We are live on ! Find out more
NRXPW

NRX Pharmaceuticals Warrant
NRXPW

Delisted

NRXPW was delisted on the 22nd of May, 2026.

Back to rankings

4 hedge funds and large institutions have $573K invested in NRX Pharmaceuticals Warrant in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% less funds holding

Funds holding: 5 → 4 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

79% less capital invested

Capital invested by funds: $2.74M → $573K (-$2.17M)

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$104

Top Sellers

Rank Fund Capital Flow
1
CCM
CAAS Capital Management
New York
-$649K
2
AC
Athanor Capital
New York
-$531K
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
1
AQR Arbitrage
Connecticut
$356K – – –
YCM
2
Yakira Capital Management
Connecticut
$145K – – –
ICM
3
Ionic Capital Management
New York
$72K – – –
CCM
4
CAAS Capital Management
New York
– -$649K -66,747 Closed
AC
5
Athanor Capital
New York
– -$531K -14,989 Closed
TRCT
6
Tower Research Capital (TRC)
New York
– +$104 +15 New

NRXPW Hedge Fund Activity: Q2 2021 in Review

4 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q2 2021, worth a combined $573K — down 79% from $2.74M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of NRXPW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $104. The largest seller was CAAS Capital Management, exiting entirely with an estimated $649K sold.

  • 4 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q2 2021, down from 5 in Q1 2021.
  • Funds reported $573K of NRX Pharmaceuticals Warrant stock for Q2 2021, down 79% quarter-over-quarter.
  • 1 fund opened new NRX Pharmaceuticals Warrant positions in Q2 2021 and 2 closed out, a net change of -1 holder.
  • The largest NRX Pharmaceuticals Warrant buyer in Q2 2021 was Tower Research Capital (TRC), an estimated $104 added.
  • The largest NRX Pharmaceuticals Warrant seller in Q2 2021 was CAAS Capital Management, an estimated $649K sold.

Based on aggregated 13F filings for Q2 2021.